Fairvalue-Calculator Fairvalue-Calculator
EN DE

MaaT Pharma SA (MAAT) Fair Value & Analysis

Healthcare · FR · Market cap €53.7M

Price€2.76
Fair Value€0.4300
Upside-84.4%
Quality95/100
Evidence: Low Range €0.3200 – €0.5400

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

MaaT Pharma SA (MAAT) currently trades at €2.76, while our model-based Fair Value estimate is €0.4300 — implying the stock looks roughly 84.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is MaaT Pharma SA (MAAT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.4300 versus a price of €2.76 — about −84% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MAAT?
Our 21-model fair value for MaaT Pharma SA is €0.4300 (as of Jun 24, 2026), built from audited fundamentals. The current price is €2.76.
What is the quality score of MAAT?
MaaT Pharma SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.